BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 30808951)

  • 1. G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma.
    Wang Y; Yang J; Wild AT; Wu WH; Shah R; Danussi C; Riggins GJ; Kannan K; Sulman EP; Chan TA; Huse JT
    Nat Commun; 2019 Feb; 10(1):943. PubMed ID: 30808951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
    Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
    Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
    [No Abstract]   [Full Text] [Related]  

  • 3. ATRX promotes heterochromatin formation to protect cells from G-quadruplex DNA-mediated stress.
    Teng YC; Sundaresan A; O'Hara R; Gant VU; Li M; Martire S; Warshaw JN; Basu A; Banaszynski LA
    Nat Commun; 2021 Jun; 12(1):3887. PubMed ID: 34162889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
    Han B; Cai J; Gao W; Meng X; Gao F; Wu P; Duan C; Wang R; Dinislam M; Lin L; Kang C; Jiang C
    Cancer Lett; 2018 Apr; 419():280-290. PubMed ID: 29378238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.
    Danussi C; Bose P; Parthasarathy PT; Silberman PC; Van Arnam JS; Vitucci M; Tang OY; Heguy A; Wang Y; Chan TA; Riggins GJ; Sulman EP; Lang FF; Creighton CJ; Deneen B; Miller CR; Picketts DJ; Kannan K; Huse JT
    Nat Commun; 2018 Mar; 9(1):1057. PubMed ID: 29535300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of ATRX in diagnosis and prognostic evaluation of glioma].
    Li Z; Piao YS; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):690-694. PubMed ID: 29050070
    [No Abstract]   [Full Text] [Related]  

  • 7. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.
    Koschmann C; Calinescu AA; Nunez FJ; Mackay A; Fazal-Salom J; Thomas D; Mendez F; Kamran N; Dzaman M; Mulpuri L; Krasinkiewicz J; Doherty R; Lemons R; Brosnan-Cashman JA; Li Y; Roh S; Zhao L; Appelman H; Ferguson D; Gorbunova V; Meeker A; Jones C; Lowenstein PR; Castro MG
    Sci Transl Med; 2016 Mar; 8(328):328ra28. PubMed ID: 26936505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers.
    Udugama M; Sanij E; Voon HPJ; Son J; Hii L; Henson JD; Chan FL; Chang FTM; Liu Y; Pearson RB; Kalitsis P; Mann JR; Collas P; Hannan RD; Wong LH
    Proc Natl Acad Sci U S A; 2018 May; 115(18):4737-4742. PubMed ID: 29669917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant ATRX: uncovering a new therapeutic target for glioma.
    Haase S; Garcia-Fabiani MB; Carney S; Altshuler D; Núñez FJ; Méndez FM; Núñez F; Lowenstein PR; Castro MG
    Expert Opin Ther Targets; 2018 Jul; 22(7):599-613. PubMed ID: 29889582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features.
    Ren Y; Zhang X; Rui W; Pang H; Qiu T; Wang J; Xie Q; Jin T; Zhang H; Chen H; Zhang Y; Lu H; Yao Z; Zhang J; Feng X
    J Magn Reson Imaging; 2019 Mar; 49(3):808-817. PubMed ID: 30194745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The chromatin remodelling factor ATRX suppresses R-loops in transcribed telomeric repeats.
    Nguyen DT; Voon HPJ; Xella B; Scott C; Clynes D; Babbs C; Ayyub H; Kerry J; Sharpe JA; Sloane-Stanley JA; Butler S; Fisher CA; Gray NE; Jenuwein T; Higgs DR; Gibbons RJ
    EMBO Rep; 2017 Jun; 18(6):914-928. PubMed ID: 28487353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERRA regulates DNA G-quadruplex formation and ATRX recruitment to chromatin.
    Tsai RX; Fang KC; Yang PC; Hsieh YH; Chiang IT; Chen Y; Lee HG; Lee JT; Chu HC
    Nucleic Acids Res; 2022 Nov; 50(21):12217-12234. PubMed ID: 36440760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.
    Qin T; Mullan B; Ravindran R; Messinger D; Siada R; Cummings JR; Harris M; Muruganand A; Pyaram K; Miklja Z; Reiber M; Garcia T; Tran D; Danussi C; Brosnan-Cashman J; Pratt D; Zhao X; Rehemtulla A; Sartor MA; Venneti S; Meeker AK; Huse JT; Morgan MA; Lowenstein PR; Castro MG; Yadav VN; Koschmann C
    Cell Rep; 2022 Jan; 38(2):110216. PubMed ID: 35021084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATRX, a guardian of chromatin.
    Aguilera P; López-Contreras AJ
    Trends Genet; 2023 Jun; 39(6):505-519. PubMed ID: 36894374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
    Karsy M; Guan J; Cohen AL; Jensen RL; Colman H
    Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATRX-dependent SVCT2 mediates macrophage infiltration in the glioblastoma xenograft model.
    Shang J; Wang Y; Li Z; Jiang L; Bai Q; Zhang X; Xiao G; Zhang J
    J Neurophysiol; 2022 May; 127(5):1309-1316. PubMed ID: 35417255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An immune signature to predict the prognosis of
    Cao W; Sun P; Luo S; Zeng Z; Xiao C; Yu W; Lei S
    Aging (Albany NY); 2023 Oct; 15(19):10453-10472. PubMed ID: 37812190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma.
    Malgulwar PB; Danussi C; Dharmaiah S; Johnson W; Singh A; Rai K; Rao A; Huse JT
    Neuro Oncol; 2024 Jan; 26(1):55-67. PubMed ID: 37625115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span.
    Watson LA; Solomon LA; Li JR; Jiang Y; Edwards M; Shin-ya K; Beier F; Bérubé NG
    J Clin Invest; 2013 May; 123(5):2049-63. PubMed ID: 23563309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies.
    Oppel F; Tao T; Shi H; Ross KN; Zimmerman MW; He S; Tong G; Aster JC; Look AT
    PLoS Genet; 2019 Apr; 15(4):e1008039. PubMed ID: 30970016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.